Actrapid

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

humani insulin

Available from:

Novo Nordisk A/S

ATC code:

A10AB01

INN (International Name):

human insulin (rDNA)

Therapeutic group:

Zdravila, ki se uporabljajo pri diabetesu

Therapeutic area:

Sladkorna bolezen

Therapeutic indications:

Zdravljenje diabetes mellitus.

Product summary:

Revision: 17

Authorization status:

Pooblaščeni

Authorization date:

2002-10-07

Patient Information leaflet

                                19
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Pred odprtjem: shranjujte v hladilniku. Ne zamrzujte.
Med uporabo: shranjujte pri temperaturi do 25 °C. Ne shranjujte v
hladilniku in ne zamrzujte.
Vialo shranjujte v zunanji ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
Iglo in injekcijsko brizgo po vsakem injiciranju zavrzite.
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novo Nordisk A/S, Novo Allé, DK-2880 Bagsvaerd, Danska
12.
ŠTEVILKE DOVOLJENJ ZA PROMET
EU/1/02/230/001
1 viala z 10 ml
EU/1/02/230/002
5 vial z 10 ml
13.
ŠTEVILKA SERIJE
Lot:
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Actrapid 40
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
20
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
NALEPKA (VIALA)
1.
IME ZDRAVILA IN POTI UPORABE
Actrapid 40 mednarodnih enot/ml
raztopina za injiciranje
humani insulin
za s.c. ali i.v. uporabo
2.
POSTOPEK
UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP/
4.
ŠTEVILKA SERIJE
Lot:
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
10 ml
6.
DRUGI PODATKI
Novo Nordisk A/S
21
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA (VIALA)
1.
IME ZDRAVILA
Actrapid 100 mednarodnih enot/ml
raztopina za injiciranje
humani insulin
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena viala vsebuje 10 ml, kar ustreza 1.000 mednarodnim enotam. 1 ml
raztopine vsebuje
100 mednarodnih enot humanega insulina (kar ustreza 3,5 mg),
3.
SEZNAM POMOŽNIH SNOVI
cinkov klorid, glicerol, metakrezol, natrijev hidroksid/klorovodikovo
kislino za uravnavanje pH in
vodo za injekcije.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
raztopina za injiciranje
1 viala z 10 ml
5 vial z 10 ml
5.
POSTOPEK IN POTI UPORABE ZDRAVILA
za subkutano ali intravensko uporabo
Pred uporabo preberite priloženo navodilo!
6.
POSEBN
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Actrapid 40 mednarodnih enot/ml raztopina za injiciranje v viali
Actrapid 100 mednarodnih enot/ml raztopina za injiciranje v viali
Actrapid Penfill 100 mednarodnih enot/ml raztopina za injiciranje v
vložku
Actrapid InnoLet 100 mednarodnih enot/ml raztopina za injiciranje v
napolnjenem injekcijskem
peresniku
Actrapid FlexPen 100 mednarodnih enot/ml raztopina za injiciranje v
napolnjenem injekcijskem
peresniku
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Actrapid viala (40 mednarodnih enot/ml)
Ena viala vsebuje 10 ml, kar ustreza 400 mednarodnim enotam. 1 ml
raztopine vsebuje
40 mednarodnih enot humanega insulina* (kar ustreza 1,4 mg).
Actrapid viala (100 mednarodnih enot/ml)
Ena viala vsebuje 10 ml, kar ustreza 1.000 mednarodnim enotam. 1 ml
raztopine vsebuje
100 mednarodnih enot humanega insulina* (kar ustreza 3,5 mg).
Actrapid Penfill
En vložek vsebuje 3 ml, kar ustreza 300 mednarodnim enotam. 1 ml
raztopine vsebuje
100 mednarodnih enot humanega insulina* (kar ustreza 3,5 mg).
Actrapid InnoLet/Actrapid FlexPen
En napolnjen injekcijski peresnik vsebuje 3 ml, kar ustreza 300
mednarodnim enotam. 1 ml raztopine
vsebuje 100 mednarodnih enot humanega insulina* (kar ustreza 3,5 mg).
_ _
*Humani insulin je pridobljen iz
_Saccharomyces cerevisiae_
s tehnologijo rekombinantne DNA.
Pomožne snovi z znanim učinkom:
Zdravilo Actrapid vsebuje manj kot 1 mmol (23 mg) natrija na odmerek,
kar v bistvu pomeni "brez
natrija".
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
raztopina za injiciranje
Raztopina je bistra, brezbarvna in vodna.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Actrapid je namenjeno zdravljenju sladkorne bolezni.
4.2
ODMERJANJE IN NAČIN UPORABE
ODMERJANJE
Moč humanega insulina izražamo v mednarodnih enotah.
3
Odmerjanje zdravila Actrapid je individualno in določeno skladno z
bolnikovimi potrebami. Zdravilo
se lahko uporablja sámo ali v kombinaciji s srednjedolgodelujočimi
ali dolgodelujočimi insuli
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 21-10-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 21-10-2020
Public Assessment Report Public Assessment Report Bulgarian 28-08-2013
Patient Information leaflet Patient Information leaflet Spanish 21-10-2020
Public Assessment Report Public Assessment Report Spanish 28-08-2013
Patient Information leaflet Patient Information leaflet Czech 21-10-2020
Public Assessment Report Public Assessment Report Czech 28-08-2013
Patient Information leaflet Patient Information leaflet Danish 21-10-2020
Public Assessment Report Public Assessment Report Danish 28-08-2013
Patient Information leaflet Patient Information leaflet German 21-10-2020
Public Assessment Report Public Assessment Report German 28-08-2013
Patient Information leaflet Patient Information leaflet Estonian 21-10-2020
Public Assessment Report Public Assessment Report Estonian 28-08-2013
Patient Information leaflet Patient Information leaflet Greek 21-10-2020
Public Assessment Report Public Assessment Report Greek 28-08-2013
Patient Information leaflet Patient Information leaflet English 21-10-2020
Public Assessment Report Public Assessment Report English 28-08-2013
Patient Information leaflet Patient Information leaflet French 21-10-2020
Public Assessment Report Public Assessment Report French 28-08-2013
Patient Information leaflet Patient Information leaflet Italian 21-10-2020
Public Assessment Report Public Assessment Report Italian 28-08-2013
Patient Information leaflet Patient Information leaflet Latvian 21-10-2020
Public Assessment Report Public Assessment Report Latvian 28-08-2013
Patient Information leaflet Patient Information leaflet Lithuanian 21-10-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-10-2020
Public Assessment Report Public Assessment Report Lithuanian 28-08-2013
Patient Information leaflet Patient Information leaflet Hungarian 21-10-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 21-10-2020
Public Assessment Report Public Assessment Report Hungarian 28-08-2013
Patient Information leaflet Patient Information leaflet Maltese 21-10-2020
Public Assessment Report Public Assessment Report Maltese 28-08-2013
Patient Information leaflet Patient Information leaflet Dutch 21-10-2020
Public Assessment Report Public Assessment Report Dutch 28-08-2013
Patient Information leaflet Patient Information leaflet Polish 21-10-2020
Public Assessment Report Public Assessment Report Polish 28-08-2013
Patient Information leaflet Patient Information leaflet Portuguese 21-10-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 21-10-2020
Public Assessment Report Public Assessment Report Portuguese 28-08-2013
Patient Information leaflet Patient Information leaflet Romanian 21-10-2020
Public Assessment Report Public Assessment Report Romanian 28-08-2013
Patient Information leaflet Patient Information leaflet Slovak 21-10-2020
Public Assessment Report Public Assessment Report Slovak 28-08-2013
Patient Information leaflet Patient Information leaflet Finnish 21-10-2020
Public Assessment Report Public Assessment Report Finnish 28-08-2013
Patient Information leaflet Patient Information leaflet Swedish 21-10-2020
Public Assessment Report Public Assessment Report Swedish 28-08-2013
Patient Information leaflet Patient Information leaflet Norwegian 21-10-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 21-10-2020
Patient Information leaflet Patient Information leaflet Icelandic 21-10-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 21-10-2020
Patient Information leaflet Patient Information leaflet Croatian 21-10-2020

Search alerts related to this product

View documents history